Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR3005 FDC vs Co-administration of BR3005-1 and BR3005-2 in Healthy Volunteers
NCT06289933Phase 1Completed
- Sponsor
- Boryung
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-Time Curve over the dosing interval and Maximum Plasma Concentration. Started Mar 2024; status: completed.
02
Drugs
dapagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06289933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289933.